CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural...

Genomics Market is anticipated to reach US$ 49,996.15 Mn by 2027

Genomics Market is anticipated to...

Bionano Genomics Symposium to feature OGM Presentations and Live Panel Discussion

Bionano Genomics Symposium to feature...

What is the Importance of Gene Editing in Farming?

What is the Importance of Gene...

Autolomous and Vineti to Establish a Fully Integrated End-To-End CGT Delivery Pathway Together

Autolomous and Vineti to Establish a...

Genome Editing: What Makes CRISPR-Cas9 a Preferred Choice?

Genome Editing: What Makes...

4 Diseases That Could Be Cured Using CRISPR Technology

4 Diseases That Could Be Cured Using...

Genome Editing Market: Development, Prospective and Regional Vision

Genome Editing Market: Development,...

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural...

Genomics Market is anticipated to reach US$ 49,996.15 Mn by 2027

Genomics Market is anticipated to...

Bionano Genomics Symposium to feature OGM Presentations and Live Panel Discussion

Bionano Genomics Symposium to feature...

What is the Importance of Gene Editing in Farming?

What is the Importance of Gene...

Autolomous and Vineti to Establish a Fully Integrated End-To-End CGT Delivery Pathway Together

Autolomous and Vineti to Establish a...

Genome Editing: What Makes CRISPR-Cas9 a Preferred Choice?

Genome Editing: What Makes...

4 Diseases That Could Be Cured Using CRISPR Technology

4 Diseases That Could Be Cured Using...

Genome Editing Market: Development, Prospective and Regional Vision

Genome Editing Market: Development,...

NeuExcell Therapeutics Appoints Russ Addis as Vice President, Research

Life Sciences Review Life Sciences Review | Tuesday, August 31, 2021
Tweet

Russ Addis joins NeuExcell Therapeutics as Vice President, Research.


FREMONT, CA: NeuExcell Therapeutics Inc. is happy to announce the immediate hiring of Russ Addis, PhD, to the newly created position of Vice President, Research.


Dr Addis will report directly to Chief Executive Officer Dr Ronald HW Lorijn and be responsible for the company's gene therapy projects. Dr Addis oversees a developing group and will expand on previous initiatives and the lab's ongoing expansion.


Dr Addis joins NeuExcell with over eight years of industry experience at numerous startup biotech businesses and several years of research at the University of Pennsylvania's Institute for Regenerative Medicine. Before joining NeuExcell, Dr Addis founded and directed Aro Biotherapeutics' research program, which focused on developing targeted genetic treatments for rare diseases. Addis is uniquely qualified to head NeuExcell's research activities due to his expertise in various therapeutic areas, including gene therapy, neurodegeneration, rare illness, ageing, and oncology.


Dr Addis earned his undergraduate degree from the University of Pennsylvania with a double major in Biochemistry and Biology and his doctorate from the Johns Hopkins University School of Medicine in Human Genetics and Molecular Biology.


Dr Lorijn states that NeuExcell is thrilled to have Russ take on this new job in a press conference. This addition to the team shows NeuExcell's growing emphasis on internal innovation to secure the company's long-term success and benefit all those affected by severe neurodegenerative diseases.


NeuExcell co-founder and Chief Scientific Advisor, Professor Gong Chen adds that Russ possesses an unmatched combination of in-depth expertise and experience in neurology, gene therapy, and regenerative medicine. NeuExcell is optimistic that Russ will accelerate our research programs' translation to the clinic.


Weekly Brief

loading
> <
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue
  • DNA Sequencing 2022

    Top Vendors

    Current Issue
  • BioTech Startups 2022

    Top Vendors

    Current Issue

Read Also

Role of Predictive Genomics in Sustainable Healthcare

Role of Predictive Genomics in Sustainable Healthcare

A Conversational AI Approach to Regulatory Intelligence

A Conversational AI Approach to Regulatory Intelligence

A rise in DNA Sequencing Market is expected in coming years

A rise in DNA Sequencing Market is expected in coming years

Omniabio Inc. Announces Private Investor

Omniabio Inc. Announces Private Investor
Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Data analysis for next-generation sequencing worth USD1.2 billion by 2026 - Cloud-based platforms emerging as preferred solutions

Lithuania's Vision to Become a Biotech Hub in Europe

Lithuania's Vision to Become a Biotech Hub in Europe

Bridging the Diversity Gap in Genomics

Bridging the Diversity Gap in Genomics

How does Biotechnology Provide Solutions to Human Needs?

How does Biotechnology Provide Solutions to Human Needs?
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/neuexcell-therapeutics-appoints-russ-addis-as-vice-president-research-nwid-532.html